J-WDMC Precision Therapeutics 

Tumor-Specific ADC-Immuno Drug Plateform with Cancer Vaccine 100% Overall Survival Rate

Tumor-Specific ADC-Immuno Drug with Zero Normal Tissue Binding

      Current ADCs targeting tumor cell membrane antigens (e.g., EGFR, HER2, Trop2, etc.) are mostly masked by a dense tumor outer cell membrane matrix (the EM assayed with cultured tumor cells; tumor cells in patient tumor have even denser membrane matrix plus a bigger tumor collagen matrix mass). The majority of current ADCs do not bind to their membrane antigens but instead bind to normal cell membranes which do not express the dense matrix, cause low efficacy and high toxicity.

      Our invention “Tumor-Specific ADC-Immuno Drug” specifically targets tumor, binds antigen on both tumor cell membrane and outer membrane matrix, zero normal tissue binding: It is low toxicity to patients. Its low DLT (dose-limiting toxicity) can maximize drug dosing and therapy efficacy.  It can reduce cancer therapy-induced patient death, side-effects, complex diseases, lifespan shortening & secondary cancers.

          In comparison, current anticancer drugs/CAR-T targeting to CEACAM5, CEACAM6, Nectin-4, BCMA, CD19, CD20, CD30, CD38, CD40, CD44v6, CD47, CD70, CD73, CTLA-4, FRα, EGFR, Caprin-1, GPC3, Integrin, PD-L1, Trop2, CLDN18.2, PSMA, HER2, HER3, DLL3, TIGIT, PTK7, VEGF, c-Met, B7-H3, & B7-H4…etc., developing by AbbVie, AstraZeneca, BMS, Eli Lilly, Gilead, GSK, Johnson & Johnson, Merck, Pfizer, Roche, & Takeda…etc., show strong binding to normal tissues. These drugs can lead to severe organ damages and life-threatening toxicities. Also, their high DLTs limit drug dosing, thus have low therapy efficacies.

Tumor-Specific ADC-Immuno Drug to Break Tumor Stroma Collagen and Tumor Cell Membrane Matrix with Cancer Vaccine 100% Overall Survival Rate

       Tumor stroma collagen barrier produced by cancer-associated fibroblasts (CAFs) and M2 tumor-associated macrophages (TAMs), together with a dense tumor cell membrane matrix, which block drugs and T cells from attacking tumor cells. Only ~1% of administered drug dose accumulates in tumor. Current drugs often give refractory late-stage patients only a few extra months of life.

Our ADC-Immuno Drug breaks these limitations.

1. Tumor-specific targeting with zero normal tissue binding, eliminate toxic side effects.

2. Native anti-tumor cells, anti-M2-TAM, anti-CAFs, saturated binding, maximize drug loading in tumor: No need for costly, complex genetic engineering, flexible linker, or multi-payload ADC design.

3. Anti-Therapy Resistance: it binds cytoplasm matrix:

(1) Resist tumor efflux pumps, maximize drug loading.

(2) Block therapy resistance.

(3) The target antigen is essential for tumor cell proliferation and survival, expressed in most cancers. Tumors cannot mutate it to resist our drug.

4. A CAR-T alternative: As an antibody platform, it natively penetrates into bone marrow and lymphatic systems to kill lymphoma & multiple myeloma tumor cells.

5. Disrupt M2-TAM- and CAFs-induced tumor collagen stroma, allow drugs and T-cells to attack tumor cells.

6. Disrupt M2-TAM-mediated:

(1) Regulatory T cell immunosuppressive shield.

(2) CD8+ T cell dysfunction.

(3) Tumor CD47 "Don't Eat Me" Signal.

(4) PD-L1/PD-1 tumor anti-T cell attack machinery.

(5) Tumor growth, drug resistance, angiogenesis, tissue remodeling.

7. Disrupt CAF-mediated:

(1) tumor collagen stroma,

(2) cytokine-driven angiogenesis,

(3) cytotoxic T-cell inactivation,

(4) M2-TAM recruitment,

(5) tumor metabolism, all of which promote metastasis and drug resistance.

# CRO-Validated Animal Study showed:

1. Our cancer vaccine achieved a 100% 100% Overall Survival Rate in monotherapy, supports the therapeutic potential of the ADC-Immuno Drug form, as ADC-immuno drug therapy is inherently stronger than vaccine therapy alone.
2. Massive Central Necrosis in tumors support the platform collapses tumor stroma architecture whether administered directly as an injected ADC or as a Cancer Vaccine.
3. The target antigen is essential for tumor survival and proliferation, expressed across nearly all cancer types. Thus, our vaccine and ADC-immunotherapy are universally applicable to solid tumor patients.

Novel Cancer vaccine with 100% Overall Survival Rate: A Universal Cancer Vaccine to Redefine Cancer Therapy Efficacy 

We can help those potential but clinical trial failed drugs to pass FDA approval easily. 

In CRO-validated animal tumor studies, when the target antigen of our Tumor-Specific-Targeting-Platform acts as a cancer vaccine, it achieved a 100% overall survival rate (10/10) as a monotherapy, without combined with cancer drug (in aggressive tumor model with 100,000 CT-26 tumor cells/mouse), compared to a 100% mortality rate in the control group. Control group tumors show active peripheral growth and visible metastatic lesions, the vaccine tumors show enlarged central necrosis with zero metastatic lesions. These indicate that the antigen of our Tumor-Specific-Targeting-Platform is real tumor specific, not present in the cell membrane of normal tissues, thus, it can act well as a target of cancer vaccine and tumor-specific ADC-immunotherapy drug.

Our single antigen, off-the-shelf cancer vaccine has strong potential in combination therapy with cancer drugs to greatly improve cancer therapy efficacy. For marketing, the combination therapy clinical trials take only about 3 years.

The result is significant, compared to Moderna cancer vaccine needs complex multiple tumor gene sequencing and computer Algorithm analysis to identify 34 neo-antigens in each patient, complex vaccine engineering, long producing time, large budget, combined with PD-1 drug, only increased 20% tumor inhibition.

#Breakthrough

1. Our vaccine can give current low efficacy cancer drugs with high therapy efficacies. Current drugs in therapy for refractory late-stage cancers often provide only transient efficacy. In combination with our vaccine, we can exponentially prolong the therapy efficacy and durability of current drugs.

2. Our vaccine can breathe new life into clinically failed oncology assets. By transforming a previously failing monotherapy drugs into an FDA-approvable combination therapy with our vaccine, our vaccine can unlock billions in stranded asset value of drug companies.

3. The oncology sector urgently needs a powerful, accessible cancer vaccine platform to break the low therapy efficacy ceiling of current  drugs. Those vaccines in clinical trials (like those targeting hTERT or Survivin) have low objective response rates (ORR). Thus, our vaccine is essential for high efficacy oncology therapy demand. 

We filed patents in 2026 to get 20+7 years patent protection in most countries worldwide. Utility of our platform:

1.      Antibody-image-guided precision cancer surgery.

2.      Antibody-image-guided precision external beam radiation therapy (EBRT).

3.      Antibody-targeted agent for Boron Neutron Capture Therapy (BNCT).

4.      Antibody-targeted proton and heavy-ion therapy.

5.      Antibody-contrast-enhanced CT, MRI, & PET tumor imaging. 

6.      CAR-T therapy and CAR-NK therapy.

7.      Antibody-cell conjugates (ACCs).

8.      T-cell receptor-mimic (TCRm) antibodies.

9.      Bispecific T-cell Engagers (BiTEs): bispecific antibody for cancer immunotherapy.

10.  Degrader-Antibody Conjugates (DACs) for targeted protein degraders to kill tumors.

11.  Antibody-drug conjugates (ADCs), antibody radio-drug conjugate (ARC), peptide-drug conjugates.

12.  Cancer vaccines: DNA, RNA, protein, & peptide cancer vaccines.

13.  Nanoparticles for targeted magnetic hyperthermia therapy & in situ vaccination.

14. Antibody-targeted ultrasound cancer therapy.

15.  Antibody-image-guided precision Interventional Oncology Therapy.

Contact: jiangmwd@gmail.com